Member Info for Soupdragon78

I see Small Pharma, the company Alastair Riddell scarpered to has been bought up by Cybin for around £17m.

https://smallpharma.com/press-release/cybin-to-acquire-small-pharma/

And Gisli Jenkins who was previously a consultant to Nuformix

https://ipf-summit.com/speaker/gisli-jenkins/

Author disclosures: R.G.J. received research support from Biogen, Galecto, GlaxoSmithKline, and Novartis Pharma; served on an advisory committee for Biogen, Boehringer Ingelheim, GlaxoSmithKline, InterMune, PharmAkea, and Roche; served as a consultant and as a speaker for Roche; served as a speaker for InterMune; served as a consultant for Nuformix and Pulmatrix; and served on a data and safety monitoring board for Boehringer Ingelheim.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800895/

Also gives a quote in the original rns in March 2021

Dr Lee Borthwick, Senior Lecturer in Fibrosis Biology at the Newcastle Fibrosis Research Group, Newcastle University, said: "The data from this most recent study of Nuformix's drug candidate, NXP002, are very encouraging in combination with current IPF drugs and show clear attenuation of both fibrosis and inflammatory markers in combination with pirfenidone or nintedanib. This reinforces previous work done in our laboratories on this compound."

Dr Anne Brindley, CEO of Nuformix, said: "IPF is a devastating disease with few treatment options and there is a real need for new therapies that are efficacious but that have better tolerability than the current therapies on the market. IPF is likely to become a combination market in the future. The results of this ex-vivo study in IPF are very encouraging and suggest the potential benefit of using NXP002 in combination with standard of care treatments for IPF. These results underpin NXP002's potential and demonstrate that further development of NXP002 for the treatment of IPF is warranted."

Lee is also the founder of Fibrofind and is speaking at the IPF summit in Boston in a couple of weeks about the use of human precision cut lung tissue samples, basically about the Nuformix work he’s been doing.

https://ipf-summit.com/speaker/lee-borthwick/

Timing not in the hands of the company, more by pure chance than anything else.

Interesting that this patent relates to the announcement of 2 March 2021 and was filed before Dans return.

Https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2023161668&_cid=P10-LM7XQB-09920-1

Abstract

The treatment of idiopathic pulmonary fibrosis (IPF) using a therapeutically effective amount of a combination of tranilast and pirfenidone, or a therapeutically effective amount of a combination of tranilast and nintedanib, is described. Tranilast may be administered as an adjunctive therapy to the treatment of IPF by either pirfenidone or nintedanib. The combination of tranilast and pirfenidone and the combination of tranilast and nintedanib may also be synergistically effective to treat IPF. Methods and pharmaceutical compositions for treating idiopathic pulmonary fibrosis (IPF) are also described

"Did this Dan fellow say ethics would not allow a stand alone clinical trial or not ?"

No he didn't say that.

He said they would be ticking that box.

(transcript from last presentation)

"...we've done a lot of that precursive work already we've seen no sort of issues in terms of any sort of tolerability red flags or anything like that so that that's simply a data package that needs to be acquired in order to move into a human studies"

Over to you Mulder, back up your statement with evidence.

Such a shame Mulder is to spineless to make their case face to face.

Just another weekend keyboard warrior.

Tried to tell us nxp004 couldn’t possibly be based on Olaparib and was wrong.

Tried to tell us that no auditor would go near the company and was wrong.

Tried posting under another username and got caught.

Thanks Mulder, I guess you don’t have the guts to ask the questions to the company.

Shame your chicken.

I take it Mulder you will be at Thursdays AGM to put this to the company face to face?

Galecto has tanked after its inhaled IPF therapy was pulled at phase II. I think this only leaves one inhaled IPF therapeutic ongoing after stage 1.

https://www.thepharmaletter.com/article/galecto-tanks-as-phase-iib-trial-of-gbo139-fails

Ok let’s say £260k cash in bank, add £70k placing money, add £70k Lanstead payments (with a further £45k likely up to October) plus £87.5k money from warrants.

So circa £530k available.

Current liabilities are £270k so if these are r&d then they can claim 30% cash from the government for this. So effectively pay £162k for the tissue work.

£530k deduct £162k gives £368k.

Over to you NFT.

Like all good teachers say… show me your working out.

Hey NFTs are you still thinking Lanstead stopped paying in July and all the SETs trades would stop like you told us so.

Some good old faces speaking at the IPF Summit in Boston next month.

Lee Borthwick of FibroFind talking about the use of Human Precision Cut Tissue slices for Anti-fibrotics testing means NFX will be indirectly on show.

https://ipf-summit.com/seminar/dynamic-fibrogenesis-in-human-precision-cut-tissue-slices-an-unrivalled-preclinical-platform-for-development-testing-of-anti-fibrotic-therapeutics

Also Ghisli Jenkins speaking (he has previously been involved with Nuformix as a consultant)

And Muhunthan Thillai who was also on the Nuformix advisory board.

https://ipf-summit.com/program/speakers/

End of March they had £260k cash, since then raised £70k and will have received circa £70k in Lanstead payments.

They will get a further £87,500 when the warrants are exercised. And can claim a research credit payment as well which will be for at least 30% of costs incurred.

The reponse is about the enablement requirement that patents must achieve, NFX have to add more detail on how to create the tranilast cocrystals so that anyone skilled in the art can carry out the necessary process.

I'm referring to the recent US patent rejection (non-final issued on 31st July 2023) where the examiner has said he does not accept such a wide description and that the company has to revise the patent to a specific treatment.

https://patentscope.wipo.int/search/en/detail.jsf?docId=US339759777&_cid=P10-LL6K3M-05439-1

The question will be which line of inflammation do NFX chose to apply their patent to now that the examiner is saying they need to choose a condition.

As I mentioned, I feel there was never the intention to formally present. Dan only mentioned the ERS in terms of having discussions with other parties.

Even if you're not presenting, its a massive networking event and chance to get in front of the right people.